Overview

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bromides
Tiotropium Bromide
Criteria
Inclusion Criteria:

- Men and women aged at least 40 years presenting with the symptoms of COPD

Exclusion Criteria:

- Patients presenting with the general and specific contraindications listed in the
Patient Information Leaflet and the Basic Product Information